Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate

International Journal of Pharmaceutics

Volumn 172, Issue 1-2, 1998, Pages 179-188

  Kawashima, Yoshiaki ^a   Serigano, Takanori ^a   Hino, Tomoaki ^a   Yamamoto, Hiromitsu ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Carrier lactose; Crystalline form; Particle morphology; Powders for inhalation

Indexed keywords

DCL 11; DCL 21; DRUG CARRIER; LACTOSE; PHARMATOSE 200M; PHARMATOSE 325M; PHARMATOSE 450M; PRANLUKAST; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; DRUG FORMULATION; DRY POWDER; FLUIDIZED BED; INHALATION; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY;

EID: 0032531782     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00202-6     Document Type: Article

References (22)

1. Bell J.H., Hartley P.S., Cox J.S.G. Dry powder aerosols. I. A new powder inhalation device. J. Pharm. Sci. 60:1971;1559-1564.
2. Byron P.R., Jashnani R., Germain S. Efficiency of aerosolization from dry powder blends of terbutaline sulfate and lactose NF with different particle size distributions. Pharm. Res. 7:1990;S81.
3. Cartilier L.H., Tawashi R. Effect of particle morphology on the flow and packing properties of lactose. S.T.P. Pharm. Sci. 3:1993;213-220.
4. Chan H.K., Clark A., Gonda I., Mumenthaler M., Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14:1997;431-437.
5. Fukumori Y., Fukuda T., Hanyu Y., Takeuchi Y., Osako Y. Coating of pharmaceutical powders by fluidized bed process. I. Aqueous enteric coating with methacrylic acid-ethylacrylate copolymer and the dissolution behavior of products. Chem. Pharm. Bull. 35:1987;2494-2957.
6. Gupta P.K., Hickey A.J. Contemporary approaches in aerosolized drug delivery to the lung. J. Control. Release. 17:1991;127-147.
7. Hallworth G.W., Westmoreland D.G. The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J. Pharm. Pharmacol. 39:1987;966-972.
8. Hersey J.A. Ordered mixing: a new concept in powder mixing practice. Powder Technol. 11:1975;41-44.
9. Hino T., Serigano T., Yamamoto H., Takeuchi H., Kawashima Y. Assessment of inertial separation techniques used for pressurized metered dose inhalers to evaluate respiratory deposition of aerosolized Wogon extract dry powder in vitro. S.T.P. Pharm. Sci. 7:1997;307-314.
10. Hino, T., Serigano, T., Yamamoto H., Takeuchi, H., Kawashima, Y., 1998. Particle design of Wogon extract dry powder for inhalation aerosols with granulation method. Int. J. Pharm., 168, 59-68.
11. Kassem N.M., Ho K.K.L., Ganderton D. The effect of air flow and carrier size on the characteristics of an inspirable cloud. J. Pharm. Pharmacol. 41:1989;14P.
12. Kassem N.M., Ganderton D. The influence of carrier surface on the characteristics of inspirable powder aerosols. J. Pharm. Pharmacol. 42:1990;11P.
13. Kawakita K., Lüdde K.H. Some consideration on powder compression equations. Powder Technol. 4:1970;61-68.
14. Kobayashi S., Kondo S., Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13:1996;80-83.
15. Lerk C.F. Consolidation and compaction of lactose. Drug Dev. Ind. Pharm. 19:1993;2359-2398.
16. Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Aishita H. In vivo pharmacologic profile of ONO-1078: A potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn. J. Pharmacol. 60:1992;217-225.
17. Niven R.W., Lott F.D., Ip A.Y., Cribbs J.M. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11:1994;1101-1109.
18. Smith, S.J., Bernstein, J.A., 1996. Therapeutic uses of lung aerosols. In: Hickey, A.J. (Ed.), Inhalation Aerosols. Marcel Dekker, New York, pp. 233-269.
19. Taniguchi Y., Tamura G., Honma M., Aizawa T., Maruyama N., Shirato K., Takishima T. The effect of an oral leukotoriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J. Allergy Clin. Immunol. 92:1993;507-512.
20. Timsina M.P., Martin G.P., Marriott C., Ganderton D., Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101:1994;1-13.
21. Visser J. Van der Waals and other cohesive forces affecting powder fluidization. Powder Techol. 58:1989;1-10.
22. Zimon, A.D., Adhesion of Dust and Powder. Plenum Press, New York, 1969, pp. 63-113.